---
title: "1. Introduction & Case Study: Post-Market Safety of Prolia"
format:
  html:
    toc: true
    toc-depth: 3
---

# Background

This lesson introduces our motivating example: evaluating the post-market cardiovascular safety of **denosumab (Prolia)** compared to **zoledronic acid**.

We'll use this as our running example throughout the workshop to illustrate the Causal Roadmap.

![Placeholder: Conceptual diagram of study design (Prolia vs. ZA).](../images/prolia_design_placeholder.png)
*Figure 1. Study schematic for the Prolia vs. Zoledronic Acid cardiovascular safety study.*
